Parkinson's Disease Biomarker Discovery: Mitochondrial Dysfunction Link

Strategic Insights -

Researchers at Oregon Health & Science University have made a significant breakthrough in the study of Parkinson's disease, uncovering a potential biomarker in peripheral blood mononuclear cells (PBMCs). The study reveals that mitochondrial dysfunction, a key driver of Parkinson's pathology, can be characterized in PBMCs, offering a novel approach to diagnosing and monitoring the disease.

Key Takeaways:

  • The study involved measuring mitochondrial bioenergetics in 13 individuals with Parkinson's disease (PD) and 15 healthy controls using the Seahorse XF platform.
  • Basal and ATP-linked respiration were elevated in the PD group, while spare capacity was decreased compared to controls.
  • The study found significant correlations between spare capacity and clinical motor function scores within the PD group.
  • PBMC mitochondrial bioenergetics may serve as a biomarker for early-stage PD and disease progression.
  • The study's findings support the potential of PBMC bioenergetics as a diagnostic tool for Parkinson's disease.

Statistics:

  • 13 individuals with PD participated in the study.
  • 15 healthy controls were included in the study.
  • Basal respiratory measurements had a markedly increased variability in the PD group compared to controls.
  • ATP-linked respiration was elevated in the PD group by 0.002 p-value.
  • Spare capacity was decreased in the PD group by 0.045 p-value.
  • Clinical motor function scores in the PD group showed significant correlations with spare capacity.

Sources:

  • Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Impaired in De Novo Parkinson's Disease. Molecular Neurobiology, 2025;62(11):14221-14226.
  • Oregon Health & Science University (OHSU).
  • Springer (www.springer.com).
  • Molecular Neurobiology (www.springerlink.com/content/0893-7648/).
  • Health & Medicine Week (October 24, 2025; p 779).